Relapsing Multiple Sclerosis (RMS) Enrolling by Invitation Phase 3 Trials for Ublituximab (DB11850)

Also known as: Multiple Sclerosis Relapse / Relapsed Multiple sclerosis / Relapsing Multiple Sclerosis / Multiple sclerosis flare

IndicationStatusPhase
DBCOND0044896 (Relapsing Multiple Sclerosis (RMS))Enrolling by Invitation3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04130997An Open Label Extension Study of Ublituximab in Subjects With Relapsing Multiple SclerosisTreatment